HSTOライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 00:51):

Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products...

Stats
本日の出来高	573.00
平均出来高	17 804.00
時価総額	1.50M
EPS	$0 ( 2024-04-04 )
次の収益日	( $0 ) 2024-06-19
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.120
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2023-06-20	Windham-bannister Susan Richards	Buy	6 835	Stock Option (right to buy)
2023-06-20	Satz Brian	Buy	6 835	Stock Option (right to buy)
2023-06-20	Kisner Daniel L	Buy	6 835	Stock Option (right to buy)
2023-06-20	Jackson Jonathan	Buy	6 835	Stock Option (right to buy)
2023-06-20	Fuhrmann Rochelle	Buy	6 835	Stock Option (right to buy)

INSIDER POWER
76.62
Last 87 transactions
Buy: 7 685 070 \| Sell: 109 431

Histogen Inc 相関

10 最も正の相関
GAINL	0.89
SVOK	0.885
TDAC	0.862
RMRM	0.86
APOP	0.847
ISNS	0.832
RNAZ	0.815

10 最も負の相関
BOCH	-0.936
SHSP	-0.877
MMAC	-0.841
NETE	-0.806

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Histogen Inc 財務諸表

Annual	2022
収益:	$3.77M
総利益:	$3.77M (100.00 %)
EPS:	$-3.26

FY	2022
収益:	$3.77M
総利益:	$3.77M (100.00 %)
EPS:	$-3.26

FY	2021
収益:	$919 000
総利益:	$699 000 (76.06 %)
EPS:	$-7.80

FY	2020
収益:	$2.06M
総利益:	$1.09M (52.99 %)
EPS:	$-41.60

Financial Reports:

No articles found.

Histogen Inc

Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products. It offers HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; HST-004, a cell conditioned media solution to treat spinal disc repair; and Emricasan, an orally active pan-caspase inhibitor for the treatment of COVID-19. The company's preclinical product candidates include CTS-2090 and CTS-2096, which are selective caspase-1 inhibitors targeting inflammasome activation, as well as intervenes in a various inflammation mediated disease. Histogen Inc. was founded in 2007 and is headquartered in San Diego, California.